Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris - Seite 2
“Determining how much a patient benefits from ADT versus the side effects is critical to making the best treatment decisions for patients with prostate cancer,” said Terry White, General Manager of Urology, Myriad Genetics. “With the addition of Absolute Risk Reduction to the Prolaris report, patients and their providers can have a more personalized risk-benefit discussion and decide on the most effective treatment path.”
For more information about Prolaris, visit: https://myriad.com/urology/understanding-the-prolaris-report/
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk
of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For
more information, visit www.myriad.com.
Lesen Sie auch
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the addition of Absolute Risk
Reduction to Prolaris and that the addition of ARR will provide patients with an individual assessment of how adding ADT to radiation therapy may reduce their risk of metastasis over 10 years.
These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K filed on March 1, 2023, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of
new information, future events or otherwise except as required by law.